Aromatase Inhibitors

Phase 3Small molecule

Aromatase Inhibitors is one of 13 small molecule programs targeting Low Grade Endometrial Stromal Sarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Grade Endometrial Stromal SarcomaRecruiting

Endocrine TherapyActive, not recruiting

Early-Stage Breast CancerNot yet recruiting

Low Grade Endometrial Stromal SarcomaPhase 2

Recruiting

Endocrine TherapyPhase 3

Active, not recruiting

Early-Stage Breast CancerPreclinical

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Endocrine Therapy

#DrugCompanyPhaseTrials

Femara

Novartis

Approved

6 2

Verzenio

Eli Lilly

Phase 3

1 3

Endocrine Therapy

Eli Lilly

Phase 3

2 4

Tykerb

GSK

Phase 2

2 5

Herceptin

Roche

Phase 2

2 6

Rozlytrek

Roche

Phase 2

1 7

Zoladex

TTerSera Therapeutics LLC

Phase 2

1 8

Aromatase Inhibitors

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Low Grade Endometrial Stromal Sarcoma

NCT03624244

Q3 2031

PreclinicalNot yet recruiting

Early-Stage Breast Cancer

NCT07596212

Q2 2034

Phase 3Active, not recruiting

Endocrine Therapy

NCT02338310

Clinical

Trials by Indication[1]

Breast Cancer14 trials

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Completed·—·Phase 3·NCT02995772·122 enrolled

HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer

Unknown status·—·Phase 4·NCT03111615·90 enrolled

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Terminated·GGeorgetown University·Phase 1/2·NCT01484041·12 enrolled

Show 11 more trials

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

Completed·HHellenic Breast Surgeons Society··NCT01298362·290 enrolled

Overcoming Endocrine Resistance in Metastatic Breast Cancer

Unknown status·CConsorzio Oncotech·Phase 3·NCT02394496·396 enrolled

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Terminated·UUniversity of Milano Bicocca·Phase 2·NCT04227327·31 enrolled

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

Completed·MMedSIR·Phase 2·NCT04240106·14 enrolled

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Completed·IIstituto Oncologico Veneto IRCCS·Phase 3·NCT02511639·110 enrolled

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Completed·—·Phase 2·NCT04352777·18 enrolled

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Unknown status·FFudan University·Phase 2·NCT01924078·100 enrolled

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated· Novartis logo

Novartis·Phase 2·NCT02213042·42 enrolled

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT02760030·14 enrolled

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Unknown status·FFuzhou General Hospital·Phase 2·NCT04088110·77 enrolled

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

Completed·EEvgen Pharma·Phase 2·NCT02970682·60 enrolled

Adjuvant1 trial

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT02914158·680 enrolled

Testosterone1 trial

Effects of Testosterone and Fat Utilization

Completed·UUniversity of Colorado, Denver·N/A·NCT03289559·13 enrolled

Low Grade Endometrial Stromal Sarcoma1 trial

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Recruiting·CCentre Leon Berard·Phase 2·NCT03624244·40 enrolled

Endocrine Therapy1 trial

Trial of Perioperative Endocrine Therapy - Individualising Care

Active, not recruiting·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT02338310·4,486 enrolled

3 more indications

Articular Cartilage1 trial

Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors

Completed·MMonash University··NCT00111241·115 enrolled

Tumor1 trial

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Completed·UUNICANCER·Phase 3·NCT03079011·1,017 enrolled

Early-stage Breast Cancer1 trial

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Not yet recruiting·UUniversity of Illinois at Chicago·Preclinical·NCT07596212·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Aromatase Inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aromatase Inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aromatase Inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Aromatase Inhibitors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q3 2031

Q2 2034

Trials by Indication[1]

Breast Cancer14 trials

Adjuvant1 trial

Testosterone1 trial

Low Grade Endometrial Stromal Sarcoma1 trial

Endocrine Therapy1 trial

Articular Cartilage1 trial

Tumor1 trial

Early-stage Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News